File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome

TitleExcess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome
Authors
Issue Date2010
Citation
Journal of Neuroscience, 2010, v. 30, n. 32, p. 10624-10638 How to Cite?
AbstractFragile X syndrome (FXS) is an inherited neurologic disease caused by loss of fragile X mental retardation protein (FMRP), which is hypothesized to mediate negative regulation ofmRNAtranslation at synapses. A prominent feature of FXS animal models is exaggerated signaling through group 1 metabotropic glutamate receptors (gp1 mGluRs), and therapeutic strategies to treat FXS are targeted mainly at gp1 mGluRs. Recent studies, however, indicate that a variety of receptor-mediated signal transduction pathways are dysregulated in FXS, suggesting that FMRP acts on a common downstream signaling molecule. Here, we show that deficiency of FMRP results in excess activity of phosphoinositide 3-kinase (PI3K), a downstream signaling molecule of many cell surface receptors. In Fmr1 knock-out neurons, excess synaptic PI3K activity can be reduced by perturbation of gp1 mGluR-mediated signaling. Remarkably, increased PI3K activity was also observed in FMRP-deficient non-neuronal cells in the absence of gp1 mGluRs. Here, we show that FMRP regulates the synthesis and synaptic localization of p110β, the catalytic subunit of PI3K. In wild type, gp1 mGluR activation induces p110β translation, p110β protein expression, and PI3K activity. In contrast, both p110β protein synthesis and PI3K activity are elevated and insensitive to gp1 mGluR stimulation in Fmr1 knock-out. This suggests that dysregulated PI3K signaling may underlie the synaptic impairments in FXS. In support of this hypothesis, we show that PI3K antagonists rescue three FXS-associated phenotypes: dysregulated synaptic protein synthesis, excess AMPA receptor internalization, and increased spine density. Targeting excessive PI3K activity might thus be a potent therapeutic strategy for FXS. Copyright © 2010 the authors.
Persistent Identifierhttp://hdl.handle.net/10722/225085
ISSN
2015 Impact Factor: 5.924
2015 SCImago Journal Rankings: 5.105

 

DC FieldValueLanguage
dc.contributor.authorGross, Christina-
dc.contributor.authorNakamoto, Mika-
dc.contributor.authorYao, Xiaodi-
dc.contributor.authorChan, Chi Bun-
dc.contributor.authorYim, So Y.-
dc.contributor.authorYe, Keqiang-
dc.contributor.authorWarren, Stephen T.-
dc.contributor.authorBassell, Gary J.-
dc.date.accessioned2016-04-18T11:16:44Z-
dc.date.available2016-04-18T11:16:44Z-
dc.date.issued2010-
dc.identifier.citationJournal of Neuroscience, 2010, v. 30, n. 32, p. 10624-10638-
dc.identifier.issn0270-6474-
dc.identifier.urihttp://hdl.handle.net/10722/225085-
dc.description.abstractFragile X syndrome (FXS) is an inherited neurologic disease caused by loss of fragile X mental retardation protein (FMRP), which is hypothesized to mediate negative regulation ofmRNAtranslation at synapses. A prominent feature of FXS animal models is exaggerated signaling through group 1 metabotropic glutamate receptors (gp1 mGluRs), and therapeutic strategies to treat FXS are targeted mainly at gp1 mGluRs. Recent studies, however, indicate that a variety of receptor-mediated signal transduction pathways are dysregulated in FXS, suggesting that FMRP acts on a common downstream signaling molecule. Here, we show that deficiency of FMRP results in excess activity of phosphoinositide 3-kinase (PI3K), a downstream signaling molecule of many cell surface receptors. In Fmr1 knock-out neurons, excess synaptic PI3K activity can be reduced by perturbation of gp1 mGluR-mediated signaling. Remarkably, increased PI3K activity was also observed in FMRP-deficient non-neuronal cells in the absence of gp1 mGluRs. Here, we show that FMRP regulates the synthesis and synaptic localization of p110β, the catalytic subunit of PI3K. In wild type, gp1 mGluR activation induces p110β translation, p110β protein expression, and PI3K activity. In contrast, both p110β protein synthesis and PI3K activity are elevated and insensitive to gp1 mGluR stimulation in Fmr1 knock-out. This suggests that dysregulated PI3K signaling may underlie the synaptic impairments in FXS. In support of this hypothesis, we show that PI3K antagonists rescue three FXS-associated phenotypes: dysregulated synaptic protein synthesis, excess AMPA receptor internalization, and increased spine density. Targeting excessive PI3K activity might thus be a potent therapeutic strategy for FXS. Copyright © 2010 the authors.-
dc.languageeng-
dc.relation.ispartofJournal of Neuroscience-
dc.titleExcess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1523/JNEUROSCI.0402-10.2010-
dc.identifier.pmid20702695-
dc.identifier.scopuseid_2-s2.0-77956209418-
dc.identifier.volume30-
dc.identifier.issue32-
dc.identifier.spage10624-
dc.identifier.epage10638-
dc.identifier.eissn1529-2401-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats